Business Description
Edwards Lifesciences Corp
NAICS : 339113
SIC : 3842
Description
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. Its key products include surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.76 | |||||
| Equity-to-Asset | 0.7 | |||||
| Debt-to-Equity | 0.12 | |||||
| Debt-to-EBITDA | 0.37 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 15.38 | |||||
| Beneish M-Score | -2.36 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.6 | |||||
| 3-Year EBITDA Growth Rate | 29.4 | |||||
| 3-Year EPS without NRI Growth Rate | 28.2 | |||||
| 3-Year FCF Growth Rate | 27.6 | |||||
| 3-Year Book Growth Rate | 22.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 6.69 | |||||
| Future 3-5Y Total Revenue Growth Rate | 10.66 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 62.61 | |||||
| 9-Day RSI | 62.32 | |||||
| 14-Day RSI | 61.1 | |||||
| 6-1 Month Momentum % | -28.21 | |||||
| 12-1 Month Momentum % | -33.44 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.03 | |||||
| Quick Ratio | 2.17 | |||||
| Cash Ratio | 1.19 | |||||
| Days Inventory | 258.82 | |||||
| Days Sales Outstanding | 42.26 | |||||
| Days Payable | 55.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.1 |
Profitability Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 79.93 | |||||
| Operating Margin % | 33.24 | |||||
| Net Margin % | 28.28 | |||||
| ROE % | 25.67 | |||||
| ROA % | 18 | |||||
| ROIC % | 24.69 | |||||
| ROC (Joel Greenblatt) % | 73.8 | |||||
| ROCE % | 23.93 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 33.66 | |||||
| Forward PE Ratio | 33.22 | |||||
| PE Ratio without NRI | 33.66 | |||||
| Shiller PE Ratio | 55.63 | |||||
| Price-to-Owner-Earnings | 59.46 | |||||
| PEG Ratio | 2.51 | |||||
| PS Ratio | 9.52 | |||||
| PB Ratio | 8.74 | |||||
| Price-to-Tangible-Book | 11.65 | |||||
| Price-to-Free-Cash-Flow | 49.65 | |||||
| Price-to-Operating-Cash-Flow | 39.42 | |||||
| EV-to-EBIT | 28.08 | |||||
| EV-to-Forward-EBIT | 28.57 | |||||
| EV-to-EBITDA | 26.54 | |||||
| EV-to-Forward-EBITDA | 25.95 | |||||
| EV-to-Revenue | 9.34 | |||||
| EV-to-Forward-Revenue | 8.6 | |||||
| EV-to-FCF | 48.34 | |||||
| Price-to-Projected-FCF | 2.93 | |||||
| Price-to-DCF (Earnings Based) | 1.17 | |||||
| Price-to-DCF (FCF Based) | 1.78 | |||||
| Price-to-Median-PS-Value | 1.13 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.56 | |||||
| Price-to-Graham-Number | 4.17 | |||||
| Price-to-Net-Current-Asset-Value | 82.95 | |||||
| Earnings Yield (Greenblatt) % | 3.56 | |||||
| Forward Rate of Return (Yacktman) % | 15.66 |
